Hence, this review summarizes recent progress in studies on TRAIL, including its role in apoptotic signaling, potential therapeutic applications of TRAIL in HCC, hepatitis virus infection, and liver fibrosis and cirrhosis.
The complete absence of IFNγ in Mdr2<sup>-/-</sup>x Ifng<sup>-/-</sup> mice reduced NK cell and CD8<sup>+</sup> T cell frequencies expressing the cytotoxic effector molecules granzyme B and TRAIL and prevented liver fibrosis.
TRAIL pDNA delivered by HCC-targeted LCPP NPs in combination with conventional sorafenib treatment attenuated HCC progression as well as liver fibrosis.
The potential for these inhibitory TRAIL receptors to protect hHSC from apoptosis opens new avenues for prognostic and therapeutic approaches to the management of liver fibrosis.